ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical is pleased to announce the 5-year results from a landmark clinical trial of LINX®, a revolutionary solution for GERD, will be presented at the upcoming Digestive Diseases Week (DDW) being held in Washington, DC from May 16th - 20th.
Dr. Robert Ganz, MD, FASGE, Chief of Gastroenterology, Abbott-Northwestern Hospital and Associate Professor of Medicine, University of Minnesota will present the clinical results:
Long-Term Results Confirm Safety and Efficacy of a Magnetic
Esophageal Device for GERD
Monday, May 18th
2:15
– 2:30 pm
Room 152
Washington DC Convention Center
Patients included in this trial had abnormal levels of acid in the esophagus and were refractory to PPI therapy. The long-term efficacy endpoints evaluated at 5-years were control of reflux-related symptoms and elimination of dependence of PPI therapy.
”With the completion of this confirmatory study, the long-term safety and clinical benefits of the LINX procedure are now undeniable. The acceptance of LINX by patients and clinicians has been remarkable, and speaks to the need for a less invasive and non-disruptive treatment that corrects the esophageal sphincter defect, the root cause of reflux disease.” said Todd Berg, President and CEO for Torax Medical.
Torax Medical will be hosting an exhibit at the meeting where attendees can participate in product demonstrations and learn more about the growing body of clinical evidence supporting LINX’s safety and efficacy. To learn more about the LINX Reflux Management System during the DDW meeting, please stop by our booth #2059 or visit www.linxforlife.com.
The LINX Reflux Management System
LINX is a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the existing esophageal sphincter’s barrier function to prevent reflux. The device is implanted using a standard minimally invasive laparoscopic procedure and is an alternative to the more anatomically disruptive fundoplication, commonly used in surgical anti-reflux procedures. The LINX Reflux Management System is indicated for those patients diagnosed with GERD as defined by abnormal pH testing, and who continue to have chronic GERD symptoms despite maximum medical therapy for the treatment of reflux.
LINX does require a surgical procedure and is associated with potential risks, contraindications and life style modifications. For more information on LINX, including a statement of risks, please visit www.linxforlife.com.
About Torax Medical
Torax Medical, Inc. is a privately-held medical device company headquartered in St. Paul, Minnesota that develops and markets products designed to treat sphincter disorders utilizing its technology platform, Magnetic Sphincter Augmentation (MSA). Torax Medical is currently marketing the LINX® Reflux Management System for the treatment of GERD in the U.S. and Europe and the FENIX® Continence Restoration System for the treatment of Fecal Incontinence (FI) in Europe. For more information, please visit www.toraxmedical.com.
